Contraindications of Neratinib

Neratinib (neratinib) is a targeted drug developed byPuma Biotechnology, Inc. for the treatment of breast cancer. It has a significant therapeutic effect on patients with HER2-positive breast cancer. However, not all breast cancer patients are suitable for neratinib, and its contraindications are detailed below.

First, the use of neratinib should be strictly contraindicated in patients with known hypersensitivity to neratinib or any of its components. Allergic reactions may include skin redness, itching, difficulty breathing, etc., and may even be life-threatening in severe cases. Therefore, before taking the drug, doctors should inquire about the patient's allergic history in detail to ensure that the patient will not have an allergic reaction to neratinib.

Secondly, neratinib has potential embryo-fetotoxicity, which may lead to serious consequences such as fetal malformation, miscarriage or stillbirth. Therefore, pregnant women should use neratinib with caution. Women of childbearing potential should take a pregnancy test to ensure they are not pregnant before receiving neratinib. At the same time, patients should use effective contraceptive measures during treatment and for at least 1 month after the last dose to avoid unwanted pregnancy. In addition, male patients with a female partner should continue to use birth control pills for at least 3 months after the last dose.

In addition, breastfeeding women should avoid breastfeeding while taking neratinib. Although there are no clear studies showing that neratinib is passed to the infant through breast milk, given the potential risks, breastfeeding women are advised to discontinue breastfeeding during treatment.

In addition to the above contraindications, there are some special groups that require caution when using neratinib. For example, patients with liver insufficiency need regular liver function tests when taking neratinib to ensure that the drug does not cause further damage to the liver. At the same time, patients with renal insufficiency also need to pay attention to the dosage and frequency of medication to avoid excessive accumulation of drugs in the body.

In short, although neratinib is an effective breast cancer treatment drug, not all breast cancer patients are suitable for use. Before use, doctors should learn more about the patient's medical history and allergies to assess whether the patient is suitable for using neratinib. At the same time, patients should follow the doctor's advice, take the medicine on time and in the right amount, and pay attention to the side effects and contraindications of the medicine. According to inquiries, neratinib has been launched in China and is included in medical insurance. Patients should consult themselves for specific information. Bangladesh also sells generic drugs produced by Yaopin International, which cost more than 3,000 yuan per box, which can alleviate a lot of the burden on patients.